Dr. Lee Rosen, MD
Claim this profileUCLA Department of Medicine
Studies Tumors
Studies Solid Tumors
9 reported clinical trials
21 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
FGFR1 positive
2Solid Tumors
Stage IV
Stage III
FGFR1 positive
Affiliated Hospitals
Clinical Trials Lee Rosen, MD is currently running
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
CX-5461
for Solid Cancers
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.
Recruiting1 award Phase 110 criteria
More about Lee Rosen, MD
Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Lee Rosen, MD has experience with
- Pembrolizumab
- Futibatinib
- OBT076
- NG-350A
- RGX-202-01
- FOLFIRI
Breakdown of trials Lee Rosen, MD has run
Solid Tumors
Neoplasms
Epithelial Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lee Rosen, MD specialize in?
Lee Rosen, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Lee Rosen, MD currently recruiting for clinical trials?
Yes, Lee Rosen, MD is currently recruiting for 3 clinical trials in Santa Monica California. If you're interested in participating, you should apply.
Are there any treatments that Lee Rosen, MD has studied deeply?
Yes, Lee Rosen, MD has studied treatments such as Pembrolizumab, Futibatinib, OBT076.
What is the best way to schedule an appointment with Lee Rosen, MD?
Apply for one of the trials that Lee Rosen, MD is conducting.
What is the office address of Lee Rosen, MD?
The office of Lee Rosen, MD is located at: UCLA Department of Medicine, Santa Monica, California 90404 United States. This is the address for their practice at the UCLA Department of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.